UNITED THERAPEUTICS Corp (UTHR)

432.69 0 (0%)

As of 2025-10-16 16:50:43 EST

United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.

Traded asNasdaq: UTHR
ISINUS91307C1027
CIK0001082554
LEI5299005C4HZL4UWROC14
EIN521984749
SectorBiotechnology
IndustryPharmaceutical Preparations
CEO—
Employees1,168
Fiscal Year End1231
Address1000 SPRING ST, SILVER SPRING, MD, 20910
Phone3016089292
Websitehttps://unither.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
UTHRUNITED THERAPEUTICS Corp2025-10-16 16:50:43432.6900
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
UTHR0001082554UNITED THERAPEUTICS CorpUS91307C10275299005C4HZL4UWROC14521984749Nasdaq2834Pharmaceutical Preparations1231DE1000 SPRING STSILVER SPRINGMD20910UNITED STATESUS30160892921000 SPRING ST, SILVER SPRING, MD, 209101000 SPRING ST, SILVER SPRING, MD, 20910—Biotechnology1996—1,168https://unither.com12,155,535,43475,381,85245,226,262United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.2025-10-10 19:33:18
This is a preview of the latest data. Subscribe to access the full data.
UTHR Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
UTHR Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202412,155,535,4343,017,303,53333.018544,912,177-2,146,368-4.5611
20239,138,231,901-1,394,108,620-13.236547,058,545756,8891.6347
202210,532,340,5212,620,240,93133.116946,301,6561,169,5542.5914
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Michael BenkowitzPresident20241,186,539——3,060,00036,12813,893,389
Paul MahonExecutive Vice President, General Counsel2024940,000——1,974,00029,5406,963,308
Martine RothblattChairperson20241,512,401——5,625,00012,20023,009,609
James EdgemondChief Financial Officer, Treasurer2024860,577——1,968,75034,4559,164,549
Paul MahonExecutive Vice President, General Counsel2023940,000——1,460,23441,0865,153,601
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20241,305
20231,168
2022985
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue2,877,400,0002,327,500,0001,936,300,000
Cost Of Revenue309,700,000257,500,000151,600,000
Gross Profit2,567,700,0002,070,000,0001,784,700,000
Research And Development Expenses481,000,000408,000,000322,900,000
General And Administrative Expenses709,700,000477,100,000482,100,000
Operating Expenses1,500,400,0001,142,600,000956,600,000
Operating Income1,377,000,0001,184,900,000979,700,000
Net Income1,195,100,000984,800,000727,300,000
Earnings Per Share Basic26.4421.0415.98
Earnings Per Share Diluted24.6419.8115
Weighted Average Shares Outstanding Basic45,200,00046,800,00045,500,000
Weighted Average Shares Outstanding Diluted48,500,00049,700,00048,500,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents1,697,200,0001,207,700,000961,200,000
Marketable Securities Current1,569,800,0001,786,400,0001,877,500,000
Accounts Receivable279,300,000278,900,000220,400,000
Inventories157,900,000111,800,000102,000,000
Non Trade Receivables———
Other Assets Current169,700,000166,200,000219,200,000
Total Assets Current3,873,900,0003,551,000,0003,380,300,000
Marketable Securities Non Current1,475,300,0001,909,800,0001,316,200,000
Property Plant And Equipment1,222,400,0001,045,400,000861,500,000
Other Assets Non Current222,100,000151,800,000114,300,000
Total Assets Non Current1,252,300,0001,069,800,000883,700,000
Total Assets7,364,000,0007,167,000,0006,044,500,000
Accounts Payable6,000,0005,600,0004,100,000
Deferred Revenue———
Short Term Debt300,000,000400,000,000—
Other Liabilities Current82,600,00071,000,00032,500,000
Total Liabilities Current738,100,000804,400,000343,200,000
Long Term Debt———
Other Liabilities Non Current181,900,00077,800,000104,600,000
Total Liabilities Non Current181,900,000377,800,000904,600,000
Total Liabilities920,000,0001,182,200,0001,247,800,000
Common Stock800,000700,000700,000
Retained Earnings7,222,200,0006,027,100,0005,042,300,000
Accumulated Other Comprehensive Income-3,400,000-12,800,000-55,500,000
Total Shareholders Equity6,444,000,0005,984,800,0004,796,700,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization72,500,00053,200,00051,300,000
Share Based Compensation Expense144,000,00039,100,000106,800,000
Other Non Cash Income Expense24,300,0004,900,000-52,500,000
Change In Accounts Receivable400,00058,500,00021,700,000
Change In Inventories46,900,00013,600,00013,400,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable42,700,00057,100,00044,500,000
Change In Other Liabilities55,600,00082,800,000150,600,000
Cash From Operating Activities1,327,100,000978,000,000802,500,000
Purchases Of Marketable Securities1,646,100,0002,514,300,0001,708,600,000
Sales Of Marketable Securities831,800,00000
Acquisition Of Property Plant And Equipment246,500,000230,400,000138,800,000
Acquisition Of Business089,200,000—
Other Investing Activities———
Cash From Investing Activities417,200,000-719,600,000-811,500,000
Tax Withholding For Share Based Compensation12,200,00013,800,00011,400,000
Payments Of Dividends———
Issuance Of Common Stock———
Repurchase Of Common Stock1,000,000,00014,700,00068,200,000
Issuance Of Long Term Debt———
Repayment Of Long Term Debt400,000,000100,000,000800,000,000
Other Financing Activities———
Cash From Financing Activities-1,254,800,000-11,900,00075,400,000
Change In Cash489,500,000246,500,00066,400,000
Cash At End Of Period1,697,200,0001,207,700,000961,200,000
Income Taxes Paid400,600,000332,500,000275,700,000
Interest Paid40,200,00056,000,00029,100,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share26.4421.0415.98
Price To Earnings Ratio13.344910.45117.4024
Earnings Growth Rate25.665431.664650.7547
Price Earnings To Growth Ratio0.520.33010.3429
Book Value Per Share142.5664127.8803105.422
Price To Book Ratio2.47491.71952.6379
Ebitda1,711,100,0001,429,800,0001,086,700,000
Enterprise Value———
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio———
Capital Expenditures249,500,000237,100,000131,900,000
Free Cash Flow1,077,600,000740,900,000670,600,000
Return On Equity0.18550.16460.1516
One Year Beta0.3970.5040.3902
Three Year Beta0.40560.48550.6038
Five Year Beta0.57860.61080.6687
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
ROTHBLATT MARTINE ADirector, Chairperson & CEO2025-10-164,000A4,130
ROTHBLATT MARTINE ADirector, Chairperson & CEO2025-10-161,500D2,630
ROTHBLATT MARTINE ADirector, Chairperson & CEO2025-10-161,654D976
ROTHBLATT MARTINE ADirector, Chairperson & CEO2025-10-16846D130
ROTHBLATT MARTINE ADirector, Chairperson & CEO2025-10-164,000D178,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Lisa McClain2025-08-13MI09Purchase2025-06-11Spouse$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
GREENWOOD CAPITAL ASSOCIATES LLC2025-09-30581,8631,388419.2097
Darwin Wealth Management, LLC2025-09-306,70716419.1875
Capital Advisors, Ltd. LLC2025-09-305,00013384.6154
Tower View Wealth Management LLC2025-09-3031,44175419.2133
BURNEY CO/2025-09-304,712,34011,241419.21
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Mid Cap FundCFMCX1,037316,036.120.0317
Pacer Funds Trust2025-07-31Pacer US Small Cap Cash Cows ETFCALF211,87058,200,6891.4543
Pacer Funds Trust2025-07-31Pacer US Large Cap Cash Cows Growth Leaders ETFCOWG38,07510,459,202.50.4498
Pacer Funds Trust2025-07-31Pacer Trendpilot US Mid Cap ETFPTMC6,3921,755,882.40.419
Pacer Funds Trust2025-07-31Pacer US Cash Cows 100 ETFCOWZ234,79664,498,461.20.3248
This is a preview of the latest data. Subscribe to access the full data.